SEC 13F Intelligence

Managers / Q4 2020 · view latest →

Boxer Capital, LLC

CIK 0001465837 · 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO, CA, 92130 · (858) 400-3112

Reported Value
$3.1B
Q4 2020
Positions
78
Filings on Record
27
2019–present window
Filed
Feb 16, 2021
original filing

Summary

Boxer Capital, LLC reported $3.1B in U.S.-listed holdings across 78 positions for Q4 2020.

Its largest position, MRTXEUR, represents 12.5% of the portfolio.

Compared with Q3 2020, the fund opened 17 new positions and exited 14.

Portfolio Metrics

Turnover
+24.6%
vs prior filed quarter
Top-10 Concentration
+51.6%
share of reported value
Largest Position
+12.5%
Mirati Therapeutics
New / Exited
17 / 14
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $809MQ4 ’18Q1 ’19: $865MQ2 ’19: $1.2BQ3 ’19: $1.4BQ3 ’19Q4 ’19: $1.8BQ1 ’20: $1.5BQ2 ’20: $2.3BQ2 ’20Q3 ’20: $2.9BQ4 ’20: $3.1BQ1 ’21: $2.9BQ1 ’21Q2 ’21: $2.8BQ3 ’21: $2.9BQ4 ’21: $2.6BQ4 ’21Q1 ’22: $1.9BQ2 ’22: $1.6BQ3 ’22: $1.8BQ3 ’22Q4 ’22: $1.9BQ2 ’23: $2MQ4 ’23: $2.0BQ4 ’23Q1 ’24: $2.0BQ2 ’24: $1.9BQ3 ’24: $2.0BQ3 ’24Q4 ’24: $0filingsflow.com

Portfolio Composition

By security type
Common Stock: 72.2%Other: 14.4%ADR: 11.6%ETP: 1.8%
  • Common Stock · 72.2% · $2.2B
  • Other · 14.4% · $447M
  • ADR · 11.6% · $360M
  • ETP · 1.8% · $57M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2020 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
SPRYSILVERBACK THERAPEUTICS INCNEW+1.68M1.68M+$78M$78M
CYTKCYTOKINETICS INCNEW+2.10M2.10M+$44M$44M
KNTEUSDKINNATE BIOPHARMA INCNEW+1.06M1.06M+$42M$42M
ALIGOS THERAPEUTICS INCNEW+1.53M1.53M+$42M$42M
MERUS N VNEW+1.43M1.43M+$25M$25M
BCABGBPBIOATLA INCNEW+686.3K686.3K+$23M$23M
32WCODIAK BIOSCIENCES INCNEW+602.6K602.6K+$19M$19M
CEREVEL THERAPEUTICS HLDNG INEW+714.5K714.5K+$12M$12M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2020

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1MRTXEURMIRATI THERAPEUTICS INChistory →COM12.47%$388M1.77M
2ONCBEIGENE LTDhistory →SPONSORED ADR9.25%$288M1.11M
3SWTXUSDSPRINGWORKS THERAPEUTICS INChistory →COM4.84%$151M2.08M
42662247DITEOS THERAPEUTICS INChistory →COM4.72%$147M4.35M
5PMVPPMV PHARMACEUTICALS INChistory →COM4.48%$140M2.27M
6RVMDREVOLUTION MEDICINES INChistory →COM4.21%$131M3.31M
7ODONATE THERAPEUTICS INCCOM3.46%$108M5.61M
8SG7SAGE THERAPEUTICS INChistory →COM3.04%$95M1.09M
9RCKTROCKET PHARMACEUTICALS INChistory →COM2.58%$80M1.47M
10SPRYSILVERBACK THERAPEUTICS INChistory →COM2.50%$78M1.68M
11SGENUSDSEATTLE GENETICS INChistory →COM2.25%$70M400.0K
12BDTXBLACK DIAMOND THERAPEUTICS Ihistory →COM2.08%$65M2.01M
13DIREXION SHS ETF TRDAILY S&P BIOTEC1.83%$57M2.25M
14RCUSARCUS BIOSCIENCES INChistory →COM1.74%$54M2.08M
15RLAYRELAY THERAPEUTICS INChistory →COM1.73%$54M1.29M
16AM6AMICUS THERAPEUTICS INChistory →COM1.73%$54M2.33M
17SNDXSYNDAX PHARMACEUTICALS INChistory →COM1.64%$51M2.29M
18ARGXARGENX SEhistory →SPONSORED ADR1.62%$50M170.9K
19PASSAGE BIO INCCOM1.58%$49M1.93M
20CYTKCYTOKINETICS INChistory →COM NEW1.40%$44M2.10M
21KNTEUSDKINNATE BIOPHARMA INChistory →COM1.36%$42M1.06M
22ALIGOS THERAPEUTICS INCCOM1.36%$42M1.53M
23NRIXNURIX THERAPEUTICS INChistory →COM1.29%$40M1.22M
24ATRECA INCCL A COM1.14%$36M2.20M
25KURAKURA ONCOLOGY INChistory →COM1.10%$34M1.05M
26SOLID BIOSCIENCES INCCOM1.03%$32M4.23M
27PANDPANDION THERAPEUTICS INChistory →COM1.01%$31M2.11M
28IDYAIDEAYA BIOSCIENCES INChistory →COM0.99%$31M2.20M
29AMARIN CORP PLCSPONS ADR NEW0.94%$29M6.00M
30MARINUS PHARMACEUTICALS INCCOM NEW0.94%$29M2.40M
31RNAGBPAVIDITY BIOSCIENCES INChistory →COM0.92%$29M1.12M
32ANABANAPTYSBIO INChistory →COM0.90%$28M1.30M
33PREVAIL THERAPEUTICS INCCOM0.83%$26M1.12M
34KDMNKADMON HLDGS INChistory →COM0.83%$26M6.21M
35MERUS N VCOM0.80%$25M1.43M
36GOSSGOSSAMER BIO INChistory →COM0.80%$25M2.56M
37BCABGBPBIOATLA INChistory →COM0.75%$23M686.3K
38CYMABAY THERAPEUTICS INCCOM0.74%$23M4.00M
39MREOMEREO BIOPHARMA GROUP PLChistory →ADS0.72%$22M6.23M
40BMRNBIOMARIN PHARMACEUTICAL INChistory →COM0.70%$22M250.0K
41AKROAKERO THERAPEUTICS INChistory →COM0.69%$21M831.5K
42NEOLEUKIN THERAPEUTICS INCCOM0.68%$21M1.50M
43THERAPEUTICS ACQUISITION CORCOM CL A0.67%$21M1.50M
44CABACABALETTA BIO INChistory →COM0.64%$20M1.60M
4532WCODIAK BIOSCIENCES INChistory →COM0.63%$19M602.6K
46TCE2CELLDEX THERAPEUTICS INC NEWhistory →COM NEW0.56%$18M1.00M
47MISTMILESTONE PHARMACEUTICALS INhistory →COM0.53%$17M2.48M
48MTNBEURMATINAS BIOPHARMA HLDGS INChistory →COM0.50%$16M11.48M
49PSTXUSDPOSEIDA THERAPEUTICS INChistory →COM0.44%$14M1.25M
50DBV TECHNOLOGIES S ASPONSORED ADR0.42%$13M7.53M

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q4 2024$01Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$2.0B68Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$1.9B61Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$2.0B59May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$2.0B52Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023Under review73Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$2M79Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023Under review75May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$1.9B71Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$1.8B73Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$1.6B76Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$1.9B74May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$2.6B71Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$2.9B88Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$2.8B95Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$2.9B85May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$3.1B78Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$2.9B75Nov 17, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$2.3B65Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$1.5B62May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.8B51Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$1.4B49Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019REVEALED$1.2B37Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$865M23May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$809M24Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.